NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
NovaBridge BiosciencesNASDAQ: NBP
Cash & Equivalents · Q4 FY2025 · quarter ended Dec 2025
Cash & equivalents falls 94.0% from a year ago
Cash & equivalents stood at $30.11M at the end of Q4 FY2025, down 94.0% from a year earlier and down 99.7% from the prior quarter. Over 3 fiscal years it compounded at -78.9% a year.
Context
- Cash & equivalents amounted to 80.8% of total assets at the end of Q4 FY2025, up 48.8 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -94.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 30.11M USD
- Year-over-year change
- —
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.11M | — |
| FY2024 | 2024-12-31 | 498.24M | +70.9% |
| FY2023 | 2023-12-31 | 291.51M | -90.9% |
| FY2022 | 2022-12-31 | 3.21B | +481.4% |
| FY2021 | 2021-12-31 | 552.8M | — |
Cash & Equivalents vs competitors
How NBP compares with its peers on the latest reported figures
- NBP's Dec 2025 cash & equivalents of $30.11M is the 6th highest of the 11 companies compared; the peer median is $39.72M.
- Its year-over-year change of -94.0% is the lowest of 11, against a peer median of +84.2%.
- Cash & equivalents amounts to 80.8% of total assets for NBP, versus a peer median of 23.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $97.6M | +98.8% | -26.7% | 29.1% | |
| Mar 2026 | $84.79M | +121.8% | -21.2% | 61.6% | |
| Mar 2026 | $49.61M | -0.4% | -18.0% | 17.4% | |
NBPNovaBridge Biosciences | Dec 2025 | $30.11M | -94.0% | -78.9% | 80.8% |
ENGNenGene Holdings Inc. | Apr 2026 | $29.83M | -48.2% | +442.5% | 9.7% |
| Mar 2026 | $14.11M | +89.9% | -1.6% | 89.5% | |
| Mar 2026 | $12.77M | -6.6% | -14.0% | 5.5% | |
| Mar 2026 | $8.44M | +68.2% | +39.9% | 7.8% | |
| Mar 2026 | $4.87M | +88.0% | +49.0% | 9.2% | |
| Peer median (excluding NBP) | $39.72M | +84.2% | +1.7% | 23.2% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 552.8M | 3.21B | 291.51M | 498.24M | 30.11M |
| Short-term Investments | 118.16M | 235.43M | 20.22M | 767.36M | 30.02K |
| Net Receivables | 60.95M | 4.81M | 1.83M | 8.55M | 256.33K |
| Inventory | 4.27M | (80.28M) | 0 | 0 | 0 |
| Other Current Assets | 0 | 242.96M | 15.68M | 1 | 0 |
| Total Current Assets | 750.18M | 3.63B | 329.91M | 1.29B | 31.1M |
| Property, Plant & Equipment (Net) | 24.87M | 123.97M | 5.55M | 27.72M | 421.59K |
| Goodwill | 25.51M | 162.57M | 0 | 0 | 0 |
| Intangible Assets | 18.77M | 118.89M | 0 | 0 | 0 |
| Long-term Investments | 55.24M | 30.85M | 0 | 224.98M | 5.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.18M | 10.91M | 33.46M | 9.96M | 402K |
| Total Non-current Assets | 128.56M | 447.19M | 39.01M | 262.66M | 6.15M |
| Total Assets | 878.74M | 4.07B | 368.92M | 1.55B | 37.24M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 2.75M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 371.66K | 2.19M | 0 | 773.67K | 0 |
| Other Current Liabilities | 0 | 549.85M | 49.67M | 5.01M | 1.31M |
| Total Current Liabilities | 97.9M | 659.74M | 58.14M | 61.7M | 3.84M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 37.49M | 0 | 106K | 0 | 0 |
| Other Non-current Liabilities | 15.2M | 373.53M | 64.83M | 3.8K | 73.05K |
| Total Non-current Liabilities | 65.52M | 405.6M | 68.19M | 22.38M | 384.13K |
| Total Liabilities | 163.42M | 1.07B | 126.34M | 84.08M | 4.23M |
| Common Stock | 19.77K | 132K | 19K | 138.68K | 3.86K |
| Retained Earnings | (683.21M) | (6.77B) | (1.26B) | (9.39B) | (190.47M) |
| Accumulated OCI | (29.26M) | 216.72M | 39.77M | 243.66M | 5.94M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 715.33M | 3.01B | 242.58M | 1.47B | 33.02M |
| Total Debt | 17.64M | 38.29M | 3.89M | 28.33M | 438.46K |
| Net Debt | (535.16M) | (3.18B) | (287.62M) | (469.9M) | (29.67M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.